Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

BACKGROUND: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system. OBJECTIVES: An existing Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban and apixaban, each compared with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Mark Access Health Policy
Autors principals: Bowrin, Kevin, Briere, Jean-Baptiste, Levy, Pierre, Millier, Aurélie, Tardu, Jean, Toumi, Mondher
Format: Artigo
Idioma:Inglês
Publicat: Routledge 2020
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7482848/
https://ncbi.nlm.nih.gov/pubmed/32944199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20016689.2020.1782164
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars